Gilead Sciences : First Quarter 2026 Supplementary Information

Published: 2026-05-07 16:14:21 ET GILD

Published on 05/07/2026 at 04:14 pm EDT

(in millions)

Mar 31

Jun 30

Sep 30

Dec 31

Mar 31

Jun 30

Sep 30

Dec 31

Mar 31

Assets

Cash, cash equivalents and marketable debt securities

$ 4,718

$ 2,772

$ 5,037

$ 9,991

$ 7,926

$ 7,126

$ 9,354

$ 10,605

$ 8,625

Accounts receivable, net

4,669

4,663

4,587

4,420

4,388

4,781

5,095

4,913

4,741

Inventories

3,363

3,388

3,435

3,589

3,778

3,913

4,387

4,368

4,339

Property, plant and equipment, net

5,321

5,346

5,391

5,414

5,421

5,459

5,500

5,606

5,638

Intangible assets, net

23,428

22,832

20,546

19,948

19,355

18,566

17,970

16,978

16,382

Goodwill

8,314

Other assets

6,479

6,265

7,215

7,319

7,253

7,563

7,914

8,239

Total assets

$ 56,292

$ 53,579

$ 54,525

$ 58,995

$ 56,434

$ 55,721

$ 58,533

$ 59,023

$ 56,278

Liabilities and Stockholders' Equity

Current liabilities

$ 13,015

$ 10,781

$ 11,725

$ 12,004

$ 12,344

$ 11,189

$ 12,298

$ 11,813

$ 9,476

Long-term liabilities

25,822

24,602

24,409

27,744

25,012

24,942

24,780

24,592

23,371

Stockholders' equity

17,455

18,197

18,390

19,246

19,078

19,590

21,456

22,618

23,431

Total liabilities and stockholders' equity

$ 56,292

$ 53,579

$ 54,525

$ 58,995

$ 56,434

$ 55,721

$ 58,533

$ 59,023

$ 56,278

‌Certain amounts and percentages may not sum or recalculate due to rounding.

2024

2025

2026

2024

2025

2026

(in millions, except percentages and per share amounts)

FY24

FY25

Revenues:

Product sales

$ 6,647

$ 6,912

$ 7,515

$ 7,536

$ 28,610

$ 6,613

$ 7,054

$ 7,345

$ 7,903

$ 28,915

$ 6,946

Royalty, contract and other revenues

144

424

527

Total revenues

6,686

6,954

7,545

7,569

28,754

6,667

7,082

7,769

7,925

29,443

6,960

Costs and expenses:

Cost of goods sold

1,552

1,544

1,574

1,581

6,251

1,540

1,501

1,569

1,623

6,234

1,445

Research and development expenses

1,520

1,351

1,395

1,641

5,907

1,379

1,491

1,346

1,584

5,799

1,372

Acquired in-process research and development expenses

4,131

505

(11)

4,663

253

170

539

1,024

107

In-process research and development impairment

2,430

1,750

4,180

190

400

590

Selling, general and administrative expenses

1,375

1,377

1,433

1,906

6,091

1,258

1,365

1,357

1,794

5,774

1,451

Total costs and expenses

11,008

4,309

6,657

5,118

27,092

4,430

4,608

4,442

5,940

19,421

4,374

Operating (loss) income

(4,322)

2,644

888

2,451

1,662

2,237

2,474

3,327

1,984

10,022

2,586

Interest expense

254

237

238

248

977

260

254

256

255

1,024

240

Other (income) expense, net

(91)

355

(306)

(6)

328

(208)

(569)

(349)

(798)

(235)

(Loss) income before income taxes

(4,486)

2,053

956

2,168

690

1,649

2,429

3,641

2,078

9,796

2,580

Income tax (benefit) expense

(315)

438

(297)

385

211

334

468

589

(105)

1,286

559

Net (loss) income

(4,170)

1,614

1,253

1,783

480

1,315

1,960

3,052

2,183

8,510

2,021

Basic (loss) earnings per share

$ (3.34)

$ 1.29

$ 1.00

$ 1.43

$ 0.38

$ 1.06

$ 1.57

$ 2.46

$ 1.76

$ 6.84

$ 1.63

Diluted (loss) earnings per share

$ (3.34)

$ 1.29

$ 1.00

$ 1.42

$ 0.38

$ 1.04

$ 1.56

$ 2.43

$ 1.74

$ 6.78

$ 1.61

Shares used in basic (loss) earnings per share calculation

1,247

1,248

1,247

1,246

1,245

1,243

1,242

1,244

1,242

Shares used in diluted (loss) earnings per share calculation

1,247

1,251

1,254

1,259

1,255

1,259

1,255

1,254

1,253

1,255

1,254

Supplemental Information:

Cash dividends declared per share

$ 0.77

$ 3.08

$ 0.79

$ 3.16

$ 0.82

Product gross margin

76.6 %

77.7 %

79.1 %

79.0 %

78.2 %

76.7 %

78.7 %

78.6 %

79.5 %

78.4 %

79.2 %

Research and development expenses as a % of revenues

22.7 %

19.4 %

18.5 %

21.7 %

20.5 %

20.7 %

21.1 %

17.3 %

20.0 %

19.7 %

Selling, general and administrative expenses as a % of revenues

20.6 %

19.8 %

19.0 %

25.2 %

21.2 %

18.9 %

19.3 %

17.5 %

22.6 %

19.6 %

20.9 %

Operating margin

(64.6)%

38.0 %

11.8 %

32.4 %

5.8 %

33.6 %

34.9 %

42.8 %

25.0 %

34.0 %

37.2 %

Effective tax rate

7.0 %

21.4 %

(31.1)%

17.8 %

30.5 %

20.2 %

19.3 %

16.2 %

(5.0)%

13.1 %

21.7 %

Certain amounts and percentages may not sum or recalculate due to rounding.

2024

2025

2026

Net cash provided by operating activities

$ 2,219

$ 1,325

$ 4,309

$ 2,975

$ 10,828

$ 1,757

$ 827

$ 4,109

$ 3,326

$ 10,019

$ 2,544

Net cash (used in) provided by investing activities

(2,207)

(307)

(710)

(225)

(3,449)

(415)

(2,116)

(427)

(1,835)

(4,793)

1,770

Net cash (used in) provided by financing activities

(1,361)

(2,953)

(1,379)

2,260

(3,433)

(3,426)

(1,566)

(1,490)

(1,263)

(7,745)

(4,239)

Effect of exchange rate changes on cash and cash equivalents

(18)

(11)

(55)

(40)

(5)

(11)

Net change in cash and cash equivalents

(1,367)

(1,947)

2,265

4,954

3,906

(2,065)

(2,782)

2,187

233

(2,428)

Cash and cash equivalents, beginning of period

6,085

4,718

2,772

5,037

6,085

9,991

7,926

5,144

7,330

9,991

7,564

Cash and cash equivalents, end of period

$ 4,718

$ 2,772

$ 5,037

$ 9,991

$ 7,926

$ 5,144

$ 7,330

$ 7,564

$ 7,628

2024

2025

2026

Net cash provided by operating activities

Purchases of property, plant and equipment

$ 2,219

(105)

$ 1,325

(130)

$ 4,309

(140)

$ 2,975

(147)

$ 10,828

(523)

$ 1,757

(104)

$ 827

(107)

$ 4,109

(147)

$ 3,326

(205)

$ 10,019

(563)

$ 2,544

(117)

Free cash flow(1)

$ 2,114

$ 1,195

$ 4,169

$ 2,828

$ 10,305

$ 1,653

$ 720

$ 3,962

$ 3,121

$ 9,456

$ 2,427

Certain amounts and percentages may not sum or recalculate due to rounding.

(1) Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section of our Press Release, issued by Gilead Sciences, Inc. on May 7, 2026 on Form 8-K, which is available on http:// investors.gilead.com.

‌2024

2025

2026

(in millions, except percentages and per share amounts)

FY24

FY25

Non-GAAP:

Cost of goods sold

$ 974

$ 965

$ 995

$ 1,002

$ 3,936

$ 961

$ 922

$ 992

$ 1,044

$ 3,919

$ 869

Research and development expenses

$ 1,403

$ 1,335

$ 1,382

$ 1,612

$ 5,732

$ 1,338

$ 1,450

$ 1,334

$ 1,565

$ 5,687

$ 1,355

Acquired in-process research and development expenses

$ 4,131

$ 38

$ 505

$ (11)

$ 4,663

$ 253

$ 61

$ 170

$ 539

$ 1,024

$ 107

Selling, general and administrative expenses

$ 1,295

$ 1,351

$ 1,405

$ 1,852

$ 5,903

$ 1,222

$ 1,358

$ 1,351

$ 1,688

$ 5,619

$ 1,363

Other (income) expense, net

$ (104)

$ (37)

$ (48)

$ (91)

$ (279)

$ (98)

$ (66)

$ (87)

$ (97)

$ (348)

$ (92)

Diluted (loss) earnings per share

$ (1.32)

$ 2.01

$ 2.02

$ 1.90

$ 4.62

$ 1.81

$ 2.01

$ 2.47

$ 1.86

$ 8.15

$ 2.03

Shares used in non-GAAP diluted (loss) earnings per share

1,247

1,251

1,254

1,259

1,255

1,259

1,255

1,254

1,253

1,255

1,254

Product gross margin

85.4 %

86.0 %

86.8 %

86.7 %

86.2 %

85.5 %

86.9 %

86.5 %

86.8 %

86.4 %

87.5 %

Research and development expenses as a % of revenues

21.0 %

19.2 %

18.3 %

21.3 %

19.9 %

20.1 %

20.5 %

17.2 %

19.7 %

19.3 %

19.5 %

Selling, general and administrative expenses as a % of revenues

19.4 %

18.6 %

24.5 %

20.5 %

18.3 %

19.2 %

17.4 %

21.3 %

19.1 %

19.6 %

Operating margin

(16.7)%

47.0 %

43.2 %

41.1 %

29.6 %

43.4 %

46.5 %

50.5 %

39.0 %

44.8 %

46.9 %

Effective tax rate

(29.8)%

17.8 %

17.5 %

19.2 %

25.9 %

16.3 %

18.8 %

17.5 %

20.5 %

18.3 %

Certain amounts and percentages may not sum or recalculate due to rounding.

(1) Please refer to our disclosures in the Non-GAAP Financial Information section of our Press Release, issued by Gilead Sciences, Inc. on May 7, 2026 on Form 8-K, which is available on http://investors.gilead.com. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 5-7.

‌2024

2025

2026

GAAP cost of goods sold

$ 1,552

$ 1,544

$ 1,574

$ 1,581

$ 6,251

$ 1,540

$ 1,501

$ 1,569

$ 1,623

$ 6,234

$ 1,445

Acquisition-related - amortization(1)

(579)

(2,316)

(579)

(577)

(576)

(2,310)

(576)

$ 3,936

(4)

$ 3,919

Restructuring - - - -

Non-GAAP cost of goods sold $ 974 $ 965 $ 995 $ 1,002

- - - (4)

$ 961 $ 922 $ 992 $ 1,044

(1)

$ 869

GAAP product gross margin

76.6 %

77.7 %

79.1 %

79.0 %

78.2 %

76.7 %

78.7 %

78.6 %

79.5 %

78.4 %

79.2 %

Acquisition-related - amortization(1)

8.7 %

8.4 %

7.7 %

8.1 %

8.8 %

8.2 %

7.9 %

7.3 %

8.0 %

8.3 %

- %

86.2 %

- %

86.4 %

Restructuring - % - % - % - % Non-GAAP product gross margin 85.4 % 86.0 % 86.8 % 86.7 % Research and development expenses reconciliation:

- % - % - % - %

85.5 % 86.9 % 86.5 % 86.8 %

- %

87.5 %

GAAP research and development expenses

$ 1,520

$ 1,351

$ 1,395

$ 1,641

$ 5,907

$ 1,379

$ 1,491

$ 1,346

$ 1,584

$ 5,799

$ 1,372

Acquisition-related - other costs(2)

(66)

(3)

(9)

(78)

(2)

(35)

(4)

(3)

(43)

(3)

(98)

$ 5,732

(69)

$ 5,687

Restructuring (50) (13) (5) (30) Non-GAAP research and development expenses $ 1,403 $ 1,335 $ 1,382 $ 1,612 IPR&D impairment reconciliation:

$ 4,180

(4,180)

$ -

$ 590

(590)

$ -

GAAP IPR&D impairment $ 2,430 $ - $ 1,750 $ - IPR&D impairment (2,430) - (1,750) -

Non-GAAP IPR&D impairment $ - $ - $ - $ -

(38) (6) (8) (16)

$ 1,338 $ 1,450 $ 1,334 $ 1,565

$ - $ 190 $ - $ 400

- (190) - (400)

$ - $ - $ - $ -

(14)

$ 1,355

$ -

GAAP selling, general and administrative expenses

$ 1,375

$ 1,377

$ 1,433

$ 1,906

$ 6,091

$ 1,258

$ 1,365

$ 1,357

$ 1,794

$ 5,774

$ 1,451

Acquisition-related - other costs(2)

(67)

(17)

(5)

(8)

(97)

Restructuring

(13)

(8)

(23)

(46)

(91)

(36)

(7)

(5)

(17)

(65)

(25)

- - - - - - - - (89) (89) (63)

$ 1,295 $ 1,351 $ 1,405 $ 1,852 $ 5,903 $ 1,222 $ 1,358 $ 1,351 $ 1,688 $ 5,619 $ 1,363

Other(3)

Non-GAAP selling, general and administrative expenses

GAAP operating (loss) income

$ (4,322)

$ 2,644

$ 888

$ 2,451

$ 1,662

$ 2,237

$ 2,474

$ 3,327

$ 1,984

$ 10,022

$ 2,586

Acquisition-related - amortization(1)

579

2,316

579

577

576

2,310

576

Acquisition-related - other costs(2)

133

174

Restructuring

188

138

IPR&D impairment

2,430

1,750

4,180

190

400

590

- - - - - - - - 89 89 63

$ (1,117) $ 3,265 $ 3,258 $ 3,114 $ 8,520 $ 2,893 $ 3,290 $ 3,921 $ 3,089 $ 13,193 $ 3,267

Other(3)

Non-GAAP operating (loss) income

- % - % - % - % - % - % - % - % 1.1 % 0.3 % 0.9 % (16.7) % 47.0 % 43.2 % 41.1 % 29.6 % 43.4 % 46.5 % 50.5 % 39.0 % 44.8 % 46.9 %

GAAP operating margin

(64.6) %

38.0 %

11.8 %

32.4 %

5.8 %

33.6 %

34.9 %

42.8 %

25.0 %

34.0 %

37.2 %

Acquisition-related - amortization(1)

8.7 %

8.3 %

7.7 %

7.6 %

8.1 %

8.7 %

8.2 %

7.4 %

7.3 %

7.8 %

8.3 %

Acquisition-related - other costs(2)

2.0 %

0.3 %

0.2 %

0.1 %

0.6 %

- %

0.5 %

- %

0.1 %

- %

Restructuring

0.9 %

0.3 %

0.4 %

1.0 %

0.7 %

1.1 %

0.2 %

0.5 %

0.6 %

IPR&D impairment

36.3 %

- %

23.2 %

- %

14.5 %

- %

2.7 %

- %

5.0 %

2.0 %

- %

Other(3)

Non-GAAP operating margin

$ (91) $ 355 $ (306) $ 35

$ 328 $ (208) $ (569) $ (349)

(14) (392) 258 (126) (426) 142 483 252

$ (104) $ (37) $ (48) $ (91) $ (98) $ (66) $ (87) $ (97)

$ (235)

142

$ (92)

$ (798)

451

$ (348)

$ (6)

(274)

$ (279)

GAAP other (income) expense, net (Loss) gain from equity securities, net

Non-GAAP other (income) expense, net

2024

2025

2026

AP (loss) income before income taxes

Acquisition-related - amortization(1)

$ (4,486) $

579

2,053

579

$ 956 $

579

2,168

579

$ 690

2,316

$ 1,649

579

$ 2,429 $

579

3,641 $

577

2,078

576

$ 9,796

2,310

$ 2,580

576

Acquisition-related - other costs(2)

133

174

Restructuring

188

138

IPR&D impairment

2,430

1,750

4,180

190

400

590

Loss (gain) from equity securities, net

392

(258)

126

274

426

(142)

(483)

(252)

(451)

(142)

- - - - - - - - 89 89 63

$ (1,267) $ 3,065 $ 3,068 $ 2,956 $ 7,822 $ 2,731 $ 3,103 $ 3,752 $ 2,930 $ 12,517 $ 3,119

Other(3)

Non-GAAP (loss) income before income taxes:

GAAP income tax (benefit) expense

$ (315)

$ 438

$ (297)

$ 385

$ 211

$ 334

$ 468

$ 589

$ (105)

$ 1,286

$ 559

Income tax effect of non-GAAP adjustments:

Acquisition-related - amortization(1)

121

484

120

118

478

118

Acquisition-related - other costs(2)

Restructuring

IPR&D impairment

611

440

1,051

137

(Gain) loss from equity securities, net

(39)

(46)

(39)

(11)

(43)

(20)

(66)

Discrete and related tax charges(4)

(39)

(60)

314

243

(42)

(48)

(11)

454

353

(46)

- - -

$ 379 $ 546 $ 538

$ 566

$ 2,028

$ 446 $ 583 $ 657

$ 601

$ 2,287

$ 570

Other(3)

Non-GAAP income tax expense

7.0 %

21.4 %

(31.1)%

17.8 %

30.5 %

20.2 %

19.3 %

16.2 %

(5.0)%

13.1 %

21.7 %

(36.8)%

(3.5)%

48.6 %

1.4 %

(4.6)%

(3.9)%

(0.5)%

1.3 %

25.6 %

5.1 %

(3.4)%

(29.8)%

17.8 %

17.5 %

19.2 %

25.9 %

16.3 %

18.8 %

17.5 %

20.5 %

18.3 %

GAAP effective tax rate

Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments(4)

Net (loss) income reconciliation:

GAAP net (loss) income

$ (4,170)

$ 1,614

$ 1,253

$ 1,783

$ 480

$ 1,315

$ 1,960

$ 3,052

$ 2,183

$ 8,510

$ 2,021

Acquisition-related - amortization(1)

458

1,832

459

457

458

1,832

458

Acquisition-related - other costs(2)

103

134

Restructuring

151

113

IPR&D impairment

1,819

1,310

3,129

139

313

453

Loss (gain) from equity securities, net

359

(212)

113

313

406

(131)

(440)

(266)

(431)

(77)

Discrete and related tax charges(4)

(314)

(29)

(243)

(454)

(353)

Non-GAAP effective tax rate

Other(3)

- -

- - -

Non-GAAP net (loss) income

$ (1,644) $ 2,519 $

2,531

$ 2,390

$ 5,795

$ 2,285 $ 2,521 $ 3,095

$ 2,329

$ 10,230

$ 2,549

Diluted (loss) earnings per share reconciliation:

GAAP diluted (loss) earnings per share

$ (3.34) $ 1.29 $

1.00

$ 1.42

$ 0.38

$ 1.04 $ 1.56 $ 2.43

$ 1.74

$ 6.78

$ 1.61

Acquisition-related - amortization(1)

0.37

0.37 0.37

0.36

1.46

0.36

0.37

0.36

0.37

1.46

0.37

Acquisition-related - other costs(2)

0.08

0.01 0.01

0.11

0.03

Restructuring

0.04

0.01 0.02

0.05

0.12

0.05

0.01

0.02

0.09

0.03

IPR&D impairment

1.46

- 1.04

2.49

0.11

0.25

0.36

Loss (gain) from equity securities, net

0.04

0.29 (0.17)

0.09

0.25

0.32

(0.10)

(0.35)

(0.21)

(0.34)

(0.06)

Discrete and related tax charges(4)

0.03

0.05 (0.25)

(0.02)

(0.19)

0.03

0.04

0.01

(0.36)

(0.28)

0.04

Other(3)

- -

0.05

Non-GAAP diluted (loss) earnings per share

$ (1.32)

$ 2.01 $ 2.02

$ 1.90

$ 4.62

$ 1.81

$ 2.01

$ 2.47

$ 1.86

$ 8.15

$ 2.03

2024

2025

2026

Cost of goods sold adjustments

$ 579

$ 2,315

$ 579

$ 579 $

577

$ 579

$ 2,314

$ 576

Research and development expenses adjustments

117

176

112

IPR&D impairment adjustments

2,430

1,750

4,180

190

400

590

Selling, general and administrative expenses adjustments

188

106

155

Total non-GAAP adjustments to costs and expenses

3,205

620

2,370

663

6,858

656

817

594

1,104

3,171

681

Other (income) expense, net, adjustments

392

(258) 126

274

426

(142) (483) (252) (451) (142)

Total non-GAAP adjustments before income taxes

3,219

1,012

2,113

789

7,132

1,082

675

112

852

2,720

539

Income tax effect of non-GAAP adjustments above

(732)

(168)

(521)

(152)

(1,574)

(154)

(162)

(79)

(252)

(647)

(58)

39 60 (314) (29) (243) 42 48 11 (454) (353) 46

$ 2,526 $ 905 $ 1,278 $ 607 $ 5,315 $ 970 $ 560 $ 43 $ 146 $ 1,719 $ 528

Discrete and related tax charges(4) Total non-GAAP adjustments after tax

Certain amounts and percentages may not sum or recalculate due to rounding.

(1) Relates to amortization of acquired intangibles.

(2) Relates primarily to integration expenses, contingent consideration fair value adjustments and other expenses associated with Gilead's recent acquisitions.

(3) The adjustments in Selling, general and administrative expenses relate to donations of equity securities to the Gilead Foundation, a California nonprofit organization, during the fourth quarter of 2025 and first quarter of 2026.

(4) Represents discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and in-process research and development, transfers of intangible assets from a foreign subsidiary to Ireland and the United States, and legal entity restructurings.

‌2024

2025

2026

(in millions)

FY24

FY25

Product sales(1):

HIV

$ 4,342

$ 4,745

$ 5,073

$ 5,452

$ 19,612

$ 4,587

$ 5,088

$ 5,277

$ 5,801

$ 20,752

$ 5,030

Liver Disease

737

832

733

719

3,021

758

795

819

844

3,217

767

Oncology

789

841

816

843

3,289

757

849

788

842

3,236

810

Other

224

280

201

184

889

209

202

184

205

799

196

Total product sales excluding Veklury

6,092

6,698

6,823

7,198

26,811

6,311

6,934

7,068

7,691

28,004

6,802

Veklury

555

214

692

337

1,799

302

121

277

212

911

144

Total product sales

6,647

6,912

7,515

7,536

28,610

6,613

7,054

7,345

7,903

28,915

6,946

Royalty, contract and other revenues

144

424

527

Total revenues

$ 6,686

$ 6,954

$ 7,545

$ 7,569

$ 28,754

$ 6,667

$ 7,082

$ 7,769

$ 7,925

$ 29,443

$ 6,960

Certain amounts and percentages may not sum or recalculate due to rounding.

(1) See Product Sales Summary on pages 9-11 for more details.

2024

2025

2026

$ 2,315

$ 2,585

$ 2,826

$ 3,129

$ 10,855

$ 2,474

$ 2,799

$ 2,940

$ 3,255

$ 11,467

$ 2,573

365

370

375

400

1,509

375

429

427

446

1,676

437

265

277

272

246

1,060

301

302

320

268

1,190

352

2,946

3,232

3,472

3,774

13,423

3,150

3,530

3,686

3,968

14,334

3,361

371

434

534

563

1,902

538

601

652

768

2,559

761

100

110

105

426

485

586

616

2,113

586

653

701

819

2,758

807

332

372

384

410

1,498

305

322

323

331

1,281

215

180

148

403

440

449

470

1,762

364

377

380

1,498

264

223

233

248

252

957

215

221

206

238

881

153

290

246

310

315

326

336

1,288

281

298

277

310

1,167

221

104

131

103

112

450

363

107

130

120

141

168

139

144

592

114

124

134

495

138

150

158

150

166

257

202

129

109

117

105

100

111

434

350

3,405

3,821

4,161

4,532

15,918

3,664

4,096

4,299

4,845

16,904

4,004

596

571

570

603

2,339

553

624

592

624

2,392

607

342

353

342

317

1,355

370

368

386

332

1,456

419

4,342

4,745

5,073

5,452

19,612

4,587

5,088

5,277

5,801

20,752

5,030

Biktarvy U.S.

Europe

Rest of World

Descovy U.S.

Europe

Rest of World

Genvoya U.S.

Europe

Rest of World

Odefsey U.S.

Europe

Rest of World

Symtuza - Revenue share(1) U.S.

Europe

Rest of World

Yeztugo U.S.

Europe

Rest of World

Other HIV(2) U.S.

Europe

Rest of World

Total HIV U.S.

Europe

Rest of World

Certain amounts and percentages may not sum or recalculate due to rounding.

(1) Represents Gilead's revenue from cobicistat ("C"), emtricitabine ("FTC") and tenofovir alafenamide ("TAF") in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

(2) Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost.

2024

2025

2026

135

342

115

105

150

373

133

248

267

222

185

922

166

184

146

140

636

141

299

292

126

374

344

405

476

385

330

1,596

346

342

309

276

1,272

283

117

126

148

486

100

122

136

149

507

119

115

100

428

140

117

132

125

514

132

225

243

232

260

959

252

280

287

1,070

237

161

134

202

299

107

113

115

100

435

121

123

126

131

501

114

385

431

393

391

1,601

335

413

414

457

1,619

362

137

142

132

134

545

168

170

158

174

671

170

215

259

207

194

876

256

211

247

212

927

235

737

832

733

719

3,021

758

795

819

844

3,217

767

Livdelzi U.S.

Europe

Rest of World

Sofosbuvir/Velpatasvir(3) U.S.

Europe

Rest of World

Vemlidy U.S.

Europe

Rest of World

Other Liver Disease(4) U.S. Europe

Rest of World

Total Liver Disease U.S. Europe

Rest of World

Veklury

315

393

108

892

199

140

470

112

284

151

169

219

150

623

290

555

214

692

337

1,799

302

121

277

212

911

144

Veklury U.S.

Europe

Rest of World

Oncology

Cell Therapy

234

153

138

158

100

107

403

344

170

186

145

161

662

160

162

123

151

595

120

158

169

182

156

666

149

154

151

143

598

146

242

303

380

414

387

390

1,570

386

393

349

368

1,495

332

225

250

208

213

896

200

203

163

183

748

150

195

206

211

193

804

180

196

186

193

755

183

274

335

480

521

485

488

1,973

464

485

432

458

1,839

407

Tecartus U.S.

Europe

Rest of World

Yescarta U.S.

Europe

Rest of World

Total Cell Therapy U.S. Europe

Rest of World

Trodelvy

206

224

226

247

902

181

224

221

251

877

253

294

347

119

173

309

320

332

355

1,315

293

364

357

384

1,397

402

431

474

433

461

1,798

381

427

384

434

1,626

403

262

275

291

269

1,098

255

291

275

281

1,102

278

113

393

121

131

129

127

508

129

789

841

816

843

3,289

757

849

788

842

3,236

810

Trodelvy U.S.

Europe

Rest of World

Total Oncology U.S.

Europe

Rest of World

Certain amounts and percentages may not sum or recalculate due to rounding.

(3) Includes Epclusa and the authorized generic version of Epclusa sold by Gilead's separate subsidiary, Asegua Therapeutics LLC ("Asegua").

(4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Sovaldi, Viread and Vosevi.

2024

2025

2026

U.S.

Europe

276

267

Rest of World

212

221

144

151

130

109

533

139

129

123

118

509

138

U.S.

255

177

Europe

Rest of World

130

356

290

U.S.

115

299

197

Europe

310

300

Rest of World

280

302

224

280

201

184

889

209

202

184

205

799

196

es U.S.

4,609

4,916

5,433

5,550

20,508

4,631

5,038

5,274

5,873

20,816

4,926

Europe

1,144

1,118

1,154

1,160

4,576

1,073

1,178

1,144

1,221

4,617

1,137

Rest of World

894

878

928

826

3,526

909

838

928

808

3,483

883

$ 6,647

$ 6,912

$ 7,515

$ 7,536

$ 28,610

$ 6,613

$ 7,054

$ 7,345

$ 7,903

$ 28,915

$ 6,946

AmBisome

Other(5)

Total Other

Total product sal

Certain amounts and percentages may not sum or recalculate due to rounding.

(5) Includes Cayston, Jyseleca, Letairis and Zydelig.

Questions? Contact [email protected]

Disclaimer

Gilead Sciences Inc. published this content on May 07, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 07, 2026 at 20:13 UTC.